Alliqua

Alliqua BioMedical was founded to leverage its proprietary electron-beam cross-linked hydrogel platform for custom contract manufacturing in advanced wound care and dermatology. Its strategic achievements included establishing a GMP facility and securing OEM partnerships. However, its core strategy shifted dramatically in 2018 through a series of transactions intended to transform the company into a clinical-stage pharmaceutical entity focused on pain, inflammation, and cannabinoid-based therapies, effectively ending its standalone contract manufacturing operations.

Proprietary electron-beam cross-linking process for manufacturing customizable hydrogel sheets that serve as delivery systems for active ingredients in wound care and dermatology.

As a contract manufacturer, competed with other CDMOs on technology and service. Post-restructuring, would have faced intense competition in pain therapeutics from large pharma and in cannabinoids from pioneers like GW Pharmaceuticals/Jazz.